In contrast to many available products that are based on in vitro methodology the BM Probe isolates cells in vivo. The BM Probe is inserted into the patients’ cubital vein through a catheter or indwelling line. This means that in most cases, no additional punctuation is necessary.
The geometry of the BM Probe was optimized to screen the largest possible volume of blood in the cubital vein. Especially for the isolation of circulating tumor cells this has the potential to detect Circulating Tumor Cells (CTCs) before liquid biopsies can.
Once the BM Probe is withdrawn, the number of isolated cells can be determined in just over an hour. This procedure is semi-automated and requires little training. Using the BM Probe, downstream molecular diagnostics are possible.
Circulating Endothelial Cells:
Endothelial cells provide the physical interface between blood and surrounding tissue. They regulate nutrient and blood component traffic. Due to mechanical or chemical reactions Endothelial Cells can detach and enter the blood stream. They are then referred to as circulating endothelial cells (CECs). CECs are low in healthy patients (4 CEC/ml) and increased in patient with Acute Conorary Artery Disease or Heart Failure patients, among others. CECs are therefore considered to be a biomarker to monitor arterial plaque disruption and treatment response.
Circulating Tumor Cells:
Circulating Tumor Cells (CTCs) represent a proven diagnostic and prognostic indicator of disease progression. They disintegrate very early from the primary tumor and travel via the blood stream to all parts of the body. This enables an earlier detection of the tumor than by using imaging technology. As is well known, the earlier the cancer is diagnosed, the more likely that it can be effectively treated. Isolating and counting the CTCs using the BM Probe has the potential to improve the effectiveness of treatment.